Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis.

Abstract

Recent evidence suggests that renal dysfunction may be a direct consequence of primary myelofibrosis (PMF). We performed a retrospective analysis of 100 patients with previously untreated PMF, receiving frontline treatment with single agent ruxolitinib, and compared them to 105 patients, receiving frontline treatment with a non-ruxolitinib-based therapy, matched by age, sex, DIPSS plus, and estimated glomerular filtration rate (eGFR). Use of ruxolitinib associated with a significantly higher rate of renal improvement (RI) > 10% (73% vs 50%, p = 0.01) confirmed on multivariate analysis (MVA) [odds ratio 3, 95% confidence interval (CI) 1.6-5.5, p < 0.001]. After a median follow-up of 41 months (range, 1-159 months), median failure-free survival (FFS) was 14 months (range, 1-117 months). Achievement of a RI > 10% maintained its independent association with prolonged FFS on MVA (hazard ratio 1.4, 95% CI 1.1-2, p = 0.02). Ruxolitinib can significantly improve renal function in patients with PMF, significantly impacting failure-free survival.

• Authors: Paolo Strati, Maen Abdelrahim, Umut Selamet, Valda D Page, Sherry A Pierce, Srdan Verstovsek, Ala Abudayyeh
• Journal: Annals of hematology (Ann Hematol) Vol. 98 Issue 7 Pg. 1611-1616 (Jul 2019) ISSN: 1432-0584 [Electronic] Germany
• PMID: 31093708 (Publication Type: Clinical Trial, Comparative Study, Journal Article)

Chemical References

• Nitriles
• Pyrazoles
• Pyrimidines
• ruxolitinib

Topics

• Adult
• Aged
• Aged, 80 and over
• Databases, Factual
• Disease-Free Survival
• Female
• Glomerular Filtration Rate (drug effects)
• Humans
• Kidney (metabolism, physiopathology)
• Male
• Middle Aged
• Nitriles
• Primary Myelofibrosis (drug therapy, metabolism, mortality, physiopathology)
• Pyrazoles (administration & dosage)
• Pyrimidines
• Retrospective Studies
• Survival Rate